{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:19:59Z","timestamp":1787883599288,"version":"build-2784847793"},"reference-count":180,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title\/>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000005298","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:02:41Z","timestamp":1734393761000},"page":"955-966","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Chronic Graft-versus-host Disease: Immune Insights, Therapeutic Advances, and Parallels for Solid Organ Transplantation"],"prefix":"10.1097","volume":"109","author":[{"given":"Julie R.","family":"Boiko","sequence":"first","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA."},{"name":"Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R.","family":"Hill","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA."},{"name":"Department of Medicine, University of Washington, Seattle, WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"R1-20250714","article-title":"Current uses and outcomes of cellular therapies: CIBMTR summary slides.","author":"Cusatis"},{"key":"R2-20250714","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2022015954","article-title":"How I diagnose and treat acute graft-versus-host disease after solid organ transplantation.","volume":"141","author":"Cooper","year":"2023","journal-title":"Blood"},{"key":"R3-20250714","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"key":"R4-20250714","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1182\/blood-2014-10-604785","article-title":"Biological significance of HLA locus matching in unrelated donor bone marrow transplantation.","volume":"125","author":"Morishima","year":"2015","journal-title":"Blood"},{"key":"R5-20250714","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fimmu.2020.00523","article-title":"Editorial: immune tolerance post allogeneic hematopoietic cell transplantation.","volume":"11","author":"Schneidawind","year":"2020","journal-title":"Front Immunol"},{"key":"R6-20250714","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/hematology.2023000427","article-title":"Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies.","volume":"2023","author":"Amanam","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R7-20250714","doi-asserted-by":"crossref","first-page":"504.e1","DOI":"10.1016\/j.jtct.2020.12.027","article-title":"Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis.","volume":"27","author":"Bachier","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R8-20250714","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","article-title":"Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.","volume":"22","author":"Arora","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-20250714","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.","volume":"116","author":"Sun","year":"2010","journal-title":"Blood"},{"key":"R10-20250714","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia.","volume":"21","author":"Boyiadzis","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R11-20250714","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"key":"R12-20250714","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.bbmt.2016.05.019","article-title":"Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation.","volume":"22","author":"Atsuta","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-20250714","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"R14-20250714","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/hematology.2023000426","article-title":"Novel approaches to acute graft-versus-host disease prevention.","volume":"2023","author":"Watkins","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R15-20250714","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/TP.0000000000002242","article-title":"Contemporary strategies and barriers to transplantation tolerance.","volume":"102","author":"Ezekian","year":"2018","journal-title":"Transplantation"},{"key":"R16-20250714","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1172\/JCI75935","article-title":"CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Invest"},{"key":"R17-20250714","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from pre-clinical and clinical studies.","volume":"129","author":"MacDonald","year":"2016","journal-title":"Blood"},{"key":"R18-20250714","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1172\/JCI90593","article-title":"Cytokine mediators of chronic graft-versus-host disease.","volume":"127","author":"MacDonald","year":"2017","journal-title":"J Clin Invest"},{"key":"R19-20250714","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease.","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1 Suppl 1","key":"R20-20250714","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbmt.2007.10.021","article-title":"Mouse models of bone marrow transplantation.","volume":"14","author":"Reddy","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-20250714","doi-asserted-by":"crossref","first-page":"700857","DOI":"10.3389\/fimmu.2021.700857","article-title":"Murine models provide new insights into pathogenesis of chronic graft-versus-host disease in humans.","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"R22-20250714","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007890-200002150-00026","article-title":"Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity.","volume":"69","author":"van den Brink","year":"2000","journal-title":"Transplantation"},{"key":"R23-20250714","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4049\/jimmunol.1300657","article-title":"Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.","volume":"191","author":"Wu","year":"2013","journal-title":"J Immunol"},{"key":"R24-20250714","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41536-023-00339-7","article-title":"Aryl hydrocarbon receptor regulates IL-22 receptor expression on thymic epithelial cell and accelerates thymus regeneration.","volume":"8","author":"Shen","year":"2023","journal-title":"NPJ Regen Med"},{"key":"R25-20250714","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1182\/bloodadvances.2022009646","article-title":"Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice.","volume":"7","author":"Zhang","year":"2023","journal-title":"Blood Adv"},{"key":"R26-20250714","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2012-12-474759","article-title":"Epithelial cytoprotection sustains ectopic expression of tissue-restricted antigens in the thymus during murine acute GVHD.","volume":"122","author":"Dertschnig","year":"2013","journal-title":"Blood"},{"key":"R27-20250714","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"R28-20250714","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbmt.2014.10.006","article-title":"Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.","volume":"21","author":"Duncan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R29-20250714","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbmt.2017.11.004","article-title":"Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone marrow transplantation for acute leukemia: implications for prophylaxis.","volume":"24","author":"Qayed","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R30-20250714","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/bloodadvances.2016002980","article-title":"Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.","volume":"1","author":"Gartlan","year":"2017","journal-title":"Blood Adv"},{"key":"R31-20250714","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood-2015-01-622662","article-title":"Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects.","volume":"126","author":"Gartlan","year":"2015","journal-title":"Blood"},{"issue":"1 Suppl","key":"R32-20250714","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.bbmt.2011.10.001","article-title":"The IL-17 differentiation pathway and its role in transplant outcome.","volume":"18","author":"Serody","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R33-20250714","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/ajt.14513","article-title":"A critical role for donor-derived IL-22 in cutaneous chronic GVHD.","volume":"18","author":"Gartlan","year":"2018","journal-title":"Am J Transplant"},{"key":"R34-20250714","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4049\/jimmunol.1400973","article-title":"Anti-IL-12\/23 p40 antibody attenuates experimental chronic graft-versus-host disease via suppression of IFN-gamma\/IL-17-producing cells.","volume":"194","author":"Okamoto","year":"2015","journal-title":"J Immunol"},{"key":"R35-20250714","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.immuni.2019.08.011","article-title":"MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota.","volume":"51","author":"Koyama","year":"2019","journal-title":"Immunity"},{"key":"R36-20250714","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2009-11-256495","article-title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma.","volume":"116","author":"Hill","year":"2010","journal-title":"Blood"},{"key":"R37-20250714","doi-asserted-by":"crossref","first-page":"e92111","DOI":"10.1172\/jci.insight.92111","article-title":"An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.","volume":"2","author":"Forcade","year":"2017","journal-title":"JCI Insight"},{"key":"R38-20250714","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"key":"R39-20250714","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/TP.0b013e3181bc267e","article-title":"Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.","volume":"88","author":"Dander","year":"2009","journal-title":"Transplantation"},{"key":"R40-20250714","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood-2013-07-514372","article-title":"Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease.","volume":"123","author":"Bruggen","year":"2014","journal-title":"Blood"},{"key":"R41-20250714","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.exphem.2016.02.002","article-title":"Effect of roflumilast, novel phosphodiesterase-4 inhibitor, on lung chronic graft-versus-host disease in mice.","volume":"44","author":"Kim","year":"2016","journal-title":"Exp Hematol"},{"key":"R42-20250714","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease.","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"key":"R43-20250714","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI17601","article-title":"Memory CD4+ T cells do not induce graft-versus-host disease.","volume":"112","author":"Anderson","year":"2003","journal-title":"J Clin Invest"},{"key":"R44-20250714","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1172\/JCI95713","article-title":"The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease.","volume":"128","author":"McDonald-Hyman","year":"2018","journal-title":"J Clin Invest"},{"key":"R45-20250714","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2016-05-715896","article-title":"Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.","volume":"128","author":"McDonald-Hyman","year":"2016","journal-title":"Blood"},{"key":"R46-20250714","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"key":"R47-20250714","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood-2015-11-680876","article-title":"Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD.","volume":"128","author":"Leveque-El Mouttie","year":"2016","journal-title":"Blood"},{"key":"R48-20250714","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.4049\/jimmunol.1301181","article-title":"Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.","volume":"191","author":"Zhang","year":"2013","journal-title":"J Immunol"},{"key":"R49-20250714","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2017-11-785865","article-title":"Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.","volume":"131","author":"Blazar","year":"2018","journal-title":"Blood"},{"key":"R50-20250714","doi-asserted-by":"crossref","first-page":"eaah7152","DOI":"10.1126\/sciimmunol.aah7152","article-title":"Eomesodermin promotes the development of type-1 regulatory T (TR1) cells.","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci Immunol"},{"key":"R51-20250714","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","article-title":"Elevated numbers of immature\/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease.","volume":"14","author":"Greinix","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R52-20250714","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","article-title":"Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.","volume":"123","author":"Flynn","year":"2014","journal-title":"Blood"},{"key":"R53-20250714","doi-asserted-by":"crossref","first-page":"e124646","DOI":"10.1172\/jci.insight.124646","article-title":"C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans.","volume":"3","author":"Verghese","year":"2018","journal-title":"JCI Insight"},{"key":"R54-20250714","doi-asserted-by":"crossref","first-page":"109746","DOI":"10.1016\/j.intimp.2023.109746","article-title":"Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.","volume":"117","author":"Chen","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R55-20250714","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2015-12-688895","article-title":"Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.","volume":"127","author":"Forcade","year":"2016","journal-title":"Blood"},{"key":"R56-20250714","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41467-017-00880-2","article-title":"Extrafollicular CD4(+) T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease.","volume":"8","author":"Deng","year":"2017","journal-title":"Nat Commun"},{"key":"R57-20250714","doi-asserted-by":"crossref","first-page":"e135468","DOI":"10.1172\/JCI135468","article-title":"Tissue-resident PSGL1loCD4+ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity.","volume":"131","author":"Kong","year":"2021","journal-title":"J Clin Invest"},{"key":"R58-20250714","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood.2020008040","article-title":"BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation.","volume":"137","author":"Jia","year":"2021","journal-title":"Blood"},{"key":"R59-20250714","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis.","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"R60-20250714","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/bloodadvances.2023010362","article-title":"Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions.","volume":"8","author":"Bracken","year":"2024","journal-title":"Blood Adv"},{"key":"R61-20250714","doi-asserted-by":"crossref","first-page":"e0137641","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice.","volume":"10","author":"Schutt","year":"2015","journal-title":"PLoS One"},{"key":"R62-20250714","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1182\/blood-2014-08-595470","article-title":"Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.","volume":"125","author":"Flynn","year":"2015","journal-title":"Blood"},{"key":"R63-20250714","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2008-09-177840","article-title":"Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.","volume":"113","author":"Sarantopoulos","year":"2009","journal-title":"Blood"},{"key":"R64-20250714","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R65-20250714","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-06-438911","article-title":"B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.","volume":"120","author":"Allen","year":"2012","journal-title":"Blood"},{"key":"R66-20250714","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2007-08-106286","article-title":"Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children\u2019s Oncology Group.","volume":"111","author":"Fujii","year":"2008","journal-title":"Blood"},{"key":"R67-20250714","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2013-10-533562","article-title":"Increased BCR responsiveness in B cells from patients with chronic GVHD.","volume":"123","author":"Allen","year":"2014","journal-title":"Blood"},{"key":"R68-20250714","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2011-07-364414","article-title":"Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.","volume":"119","author":"Srinivasan","year":"2012","journal-title":"Blood"},{"key":"R69-20250714","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2015-09-668145","article-title":"Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice.","volume":"127","author":"Jin","year":"2016","journal-title":"Blood"},{"key":"R70-20250714","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1182\/bloodadvances.2017009068","article-title":"Inhibition of the IRE-1alpha\/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice.","volume":"2","author":"Schutt","year":"2018","journal-title":"Blood Adv"},{"key":"R71-20250714","doi-asserted-by":"crossref","first-page":"705484","DOI":"10.3389\/fimmu.2021.705484","article-title":"XBP-1s promotes B cell pathogenicity in chronic GVHD by restraining the activity of regulated IRE-1alpha-dependent decay.","volume":"12","author":"Choi","year":"2021","journal-title":"Front Immunol"},{"key":"R72-20250714","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2004-09-3660","article-title":"Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.","volume":"105","author":"Miklos","year":"2005","journal-title":"Blood"},{"key":"R73-20250714","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","article-title":"Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease.","volume":"110","author":"Svegliati","year":"2007","journal-title":"Blood"},{"key":"R74-20250714","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4049\/jimmunol.1200677","article-title":"Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.","volume":"189","author":"Young","year":"2012","journal-title":"J Immunol"},{"key":"R75-20250714","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1182\/blood-2017-04-779934","article-title":"Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease.","volume":"131","author":"Yamakawa","year":"2018","journal-title":"Blood"},{"key":"R76-20250714","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.4049\/jimmunol.2200558","article-title":"Nestin+ mesenchymal stromal cells fibrotic transition mediated by CD169+ macrophages in bone marrow chronic graft-versus-host disease.","volume":"211","author":"Zhang","year":"2023","journal-title":"J Immunol"},{"key":"R77-20250714","doi-asserted-by":"crossref","first-page":"e0133216","DOI":"10.1371\/journal.pone.0133216","article-title":"Humanized chronic graft-versus-host disease in NOD-SCID il2rgamma-\/- (NSG) mice with G-CSF-mobilized peripheral blood mononuclear cells following cyclophosphamide and total body irradiation.","volume":"10","author":"Fujii","year":"2015","journal-title":"PLoS One"},{"key":"R78-20250714","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2017.04.019","article-title":"Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease.","volume":"23","author":"Inamoto","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R79-20250714","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood.2021011671","article-title":"Donor bone marrow-derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice.","volume":"139","author":"Adams","year":"2022","journal-title":"Blood"},{"key":"R80-20250714","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00007890-199501000-00006","article-title":"Survival of MHC-deficient mouse heterotopic cardiac allografts.","volume":"59","author":"Campos","year":"1995","journal-title":"Transplantation"},{"key":"R81-20250714","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0966-3274(99)80017-3","article-title":"Assessment of peripheral tolerance in anti-CD4 treated C57BL\/6 mouse heart transplants recipients.","volume":"7","author":"Han","year":"1999","journal-title":"Transpl Immunol"},{"key":"R82-20250714","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1097\/00007890-199812150-00015","article-title":"Redefining peripheral tolerance in the BALB\/c to CBA mouse cardiac allograft model: vascular and cytokine analysis after transient CD4 T cell depletion.","volume":"66","author":"Mottram","year":"1998","journal-title":"Transplantation"},{"key":"R83-20250714","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ajt.12526","article-title":"Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection.","volume":"14","author":"Kim","year":"2014","journal-title":"Am J Transplant"},{"key":"R84-20250714","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.3389\/fimmu.2018.03038","article-title":"Germinal center alloantibody responses mediate progression of chronic allograft injury.","volume":"9","author":"Chhabra","year":"2018","journal-title":"Front Immunol"},{"key":"R85-20250714","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1172\/JCI28031","article-title":"IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants.","volume":"117","author":"Burlingham","year":"2007","journal-title":"J Clin Invest"},{"key":"R86-20250714","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1600-6143.2011.03482.x","article-title":"Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation.","volume":"11","author":"Fan","year":"2011","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"R87-20250714","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000512659","article-title":"Preceding T-cell-mediated rejection is associated with the development of chronic active antibody-mediated rejection by de novo donor-specific antibody.","volume":"144","author":"Tsuji","year":"2020","journal-title":"Nephron"},{"key":"R88-20250714","doi-asserted-by":"crossref","first-page":"e1002572","DOI":"10.1371\/journal.pmed.1002572","article-title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis.","volume":"15","author":"Bouquegneau","year":"2018","journal-title":"PLoS Med"},{"key":"R89-20250714","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"R90-20250714","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3389\/fimmu.2020.00919","article-title":"Distribution of de novo donor-specific antibody subclasses quantified by mass spectrometry: high IgG3 proportion is associated with antibody-mediated rejection occurrence and severity.","volume":"11","author":"Pernin","year":"2020","journal-title":"Front Immunol"},{"key":"R91-20250714","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1111\/ajt.15088","article-title":"The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R92-20250714","doi-asserted-by":"crossref","first-page":"861471","DOI":"10.3389\/fimmu.2022.861471","article-title":"The inhibition of CD40\/CD154 costimulatory signaling in the prevention of renal transplant rejection in nonhuman primates: a systematic review and meta analysis.","volume":"13","author":"Perrin","year":"2022","journal-title":"Front Immunol"},{"key":"R93-20250714","doi-asserted-by":"crossref","first-page":"657894","DOI":"10.3389\/fimmu.2021.657894","article-title":"Disruption of Tfh:B cell interactions prevents antibody-mediated rejection in a kidney transplant model in rats: impact of calcineurin inhibitor dose.","volume":"12","author":"Steines","year":"2021","journal-title":"Front Immunol"},{"key":"R94-20250714","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/ajt.16484","article-title":"Follicular T cells mediate donor-specific antibody and rejection after solid organ transplantation.","volume":"21","author":"Mohammed","year":"2021","journal-title":"Am J Transplant"},{"key":"R95-20250714","first-page":"2580","article-title":"Antibody-mediated rejection of solid-organ allografts.","volume":"379","author":"Lefaucheur","year":"2018","journal-title":"N Engl J Med"},{"key":"R96-20250714","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion.","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"key":"R97-20250714","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3389\/fimmu.2017.00306","article-title":"IL-21 receptor antagonist inhibits differentiation of B cells toward plasmablasts upon alloantigen stimulation.","volume":"8","author":"de Leur","year":"2017","journal-title":"Front Immunol"},{"key":"R98-20250714","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/ajt.14142","article-title":"Renal operational tolerance is associated with a defect of blood Tfh cells that exhibit impaired B cell help.","volume":"17","author":"Chenouard","year":"2017","journal-title":"Am J Transplant"},{"key":"R99-20250714","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ajt.16004","article-title":"Superior inhibition of alloantibody responses with selective CD28 blockade is CTLA-4 dependent and T follicular helper cell specific.","volume":"21","author":"La Muraglia","year":"2021","journal-title":"Am J Transplant"},{"key":"R100-20250714","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.transproceed.2020.06.033","article-title":"Mechanism of graft damage caused by NTPDase1-activated macrophages in acute antibody-mediated rejection.","volume":"53","author":"Peng","year":"2021","journal-title":"Transplant Proc"},{"key":"R101-20250714","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1600-6143.2011.03633.x","article-title":"Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and are protective biomarkers for kidney graft outcome.","volume":"11","author":"Bestard","year":"2011","journal-title":"Am J Transplant"},{"key":"R102-20250714","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12865-019-0308-x","article-title":"Increased circulating Tfh to Tfr ratio in chronic renal allograft dysfunction: a pilot study.","volume":"20","author":"Yan","year":"2019","journal-title":"BMC Immunol"},{"key":"R103-20250714","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.4049\/jimmunol.1400280","article-title":"Myeloid PTEN deficiency protects livers from ischemia reperfusion injury by facilitating M2 macrophage differentiation.","volume":"192","author":"Yue","year":"2014","journal-title":"J Immunol"},{"key":"R104-20250714","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/ajt.12803","article-title":"The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation.","volume":"14","author":"Toki","year":"2014","journal-title":"Am J Transplant"},{"key":"R105-20250714","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ajt.13014","article-title":"Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants.","volume":"15","author":"Kaul","year":"2015","journal-title":"Am J Transplant"},{"key":"R106-20250714","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","article-title":"Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.","volume":"24","author":"Stewart","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R107-20250714","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1523-1755.2005.00606.x","article-title":"Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status.","volume":"68","author":"Tinckam","year":"2005","journal-title":"Kidney Int"},{"key":"R108-20250714","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/ctr.12348","article-title":"Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA antigens.","volume":"28","author":"Xu","year":"2014","journal-title":"Clin Transplant"},{"key":"R109-20250714","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/j.1600-6143.2007.01997.x","article-title":"Macrophage depletion suppresses cardiac allograft vasculopathy in mice.","volume":"7","author":"Kitchens","year":"2007","journal-title":"Am J Transplant"},{"key":"R110-20250714","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/ajt.14602","article-title":"Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury.","volume":"18","author":"Zhao","year":"2018","journal-title":"Am J Transplant"},{"key":"R111-20250714","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1681\/ASN.2016050573","article-title":"Macrophage-to-myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft injury.","volume":"28","author":"Wang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R112-20250714","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1172\/JCI32311","article-title":"Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis.","volume":"117","author":"Babu","year":"2007","journal-title":"J Clin Invest"},{"key":"R113-20250714","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MOT.0b013e3282f3df15","article-title":"Lymphoid neogenesis in chronic rejection.","volume":"13","author":"Thaunat","year":"2008","journal-title":"Curr Opin Organ Transplant"},{"key":"R114-20250714","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"R115-20250714","doi-asserted-by":"crossref","first-page":"e174184","DOI":"10.1172\/JCI174184","article-title":"IL-6-mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation.","volume":"134","author":"Zhang","year":"2024","journal-title":"J Clin Invest"},{"key":"R116-20250714","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report.","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R117-20250714","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0022034515570942","article-title":"Oral disease profiles in chronic graft versus host disease.","volume":"94","author":"Bassim","year":"2015","journal-title":"J Dent Res"},{"key":"R118-20250714","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.bbmt.2010.03.023","article-title":"Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation.","volume":"16","author":"Imanguli","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R119-20250714","doi-asserted-by":"crossref","first-page":"903154","DOI":"10.3389\/froh.2022.903154","article-title":"Oral chronic graft-versus-host disease.","volume":"3","author":"Dean","year":"2022","journal-title":"Front Oral Health"},{"key":"R120-20250714","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s12185-018-2520-5","article-title":"Graft-versus-host disease (GvHD) of the tongue and of the oral cavity: a large retrospective study.","volume":"108","author":"Piccin","year":"2018","journal-title":"Int J Hematol"},{"key":"R121-20250714","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2012.04.009","article-title":"Extensive dental caries in patients with oral chronic graft-versus-host disease.","volume":"18","author":"Castellarin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"R122-20250714","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41409-020-0933-2","article-title":"Management and long-term consequences of genital graft versus host disease following hematopoietic stem cell transplantation.","volume":"55","author":"Lev-Sagie","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R123-20250714","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbmt.2015.09.021","article-title":"Graft-versus-host disease-associated vulvovaginal symptoms after bone marrow transplantation.","volume":"22","author":"Chung","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R124-20250714","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4103\/IJO.IJO_2839_22","article-title":"A brief account on ocular graft versus host disease.","volume":"71","author":"Chatterjee","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R125-20250714","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/blood-2012-10-464198","article-title":"Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"key":"R126-20250714","doi-asserted-by":"crossref","first-page":"00185","DOI":"10.1183\/23120541.00185-2022","article-title":"Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions.","volume":"8","author":"Glanville","year":"2022","journal-title":"ERJ Open Res"},{"key":"R127-20250714","doi-asserted-by":"crossref","first-page":"1702617","DOI":"10.1183\/13993003.02617-2017","article-title":"Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation.","volume":"51","author":"Bergeron","year":"2018","journal-title":"Eur Respir J"},{"key":"R128-20250714","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1182\/blood-2011-04-349068","article-title":"Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.","volume":"118","author":"Jacobsohn","year":"2011","journal-title":"Blood"},{"key":"R129-20250714","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1001\/jamaoncol.2021.3676","article-title":"Trends in late mortality and life expectancy after allogeneic blood or marrow transplantation over 4 decades: a blood or marrow transplant survivor study report.","volume":"7","author":"Bhatia","year":"2021","journal-title":"JAMA Oncol"},{"key":"R130-20250714","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R131-20250714","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.bbmt.2017.04.017","article-title":"Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age.","volume":"23","author":"Vrooman","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R132-20250714","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"R133-20250714","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jtct.2021.10.002","article-title":"Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis.","volume":"28","author":"Bhatt","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R134-20250714","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41409-023-01930-8","article-title":"Clinical and economic burden associated with graft-versus-host disease following allogeneic hematopoietic cell transplantation in France.","volume":"58","author":"Michonneau","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R135-20250714","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.bbmt.2018.09.031","article-title":"Characteristics of late fatal infections after allogeneic hematopoietic cell transplantation.","volume":"25","author":"Norkin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R136-20250714","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood-2012-04-424135","article-title":"Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.","volume":"120","author":"Jacobsohn","year":"2012","journal-title":"Blood"},{"key":"R137-20250714","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbmt.2013.11.025","article-title":"Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.","volume":"20","author":"Palmer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R138-20250714","doi-asserted-by":"crossref","first-page":"97.e1","DOI":"10.1016\/j.jtct.2023.10.010","article-title":"Severity of chronic graft-versus-host disease and late effects following allogeneic hematopoietic cell transplantation for adults with hematologic malignancy.","volume":"30","author":"Lee","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R139-20250714","doi-asserted-by":"crossref","first-page":"712.e1","DOI":"10.1016\/j.jtct.2022.07.014","article-title":"Association of chronic graft-versus-host disease with late effects following allogeneic hematopoietic cell transplantation for children with hematologic malignancy.","volume":"28","author":"Lee","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R140-20250714","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pcl.2009.11.008","article-title":"The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children.","volume":"57","author":"Baker","year":"2010","journal-title":"Pediatr Clin North Am"},{"key":"R141-20250714","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/bloodadvances.2019001126","article-title":"Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.","volume":"4","author":"Lee","year":"2020","journal-title":"Blood Adv"},{"key":"R142-20250714","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2006-10-054080","article-title":"Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation.","volume":"110","author":"Tichelli","year":"2007","journal-title":"Blood"},{"key":"R143-20250714","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation.","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"key":"R144-20250714","doi-asserted-by":"crossref","first-page":"470.e1","DOI":"10.1016\/j.jtct.2023.04.004","article-title":"Impact of chronic graft-versus-host disease on patient employment, income, and informal caregiver burden: findings from the living with chronic GVHD patient survey.","volume":"29","author":"Yu","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R145-20250714","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease.","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R146-20250714","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/bmt.2010.5","article-title":"Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation.","volume":"45","author":"Pallua","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"R147-20250714","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.bbmt.2018.07.020","article-title":"Impact of psychological distress on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.","volume":"24","author":"El-Jawahri","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R148-20250714","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2014-03-563544","article-title":"Failure-free survival after initial systemic treatment of chronic graft-versus-host disease.","volume":"124","author":"Inamoto","year":"2014","journal-title":"Blood"},{"key":"R149-20250714","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.bbmt.2015.07.025","article-title":"Long-term morbidity and mortality in children with chronic graft-versus-host disease classified by national institutes of health consensus criteria after allogeneic hematopoietic stem cell transplantation.","volume":"21","author":"Inagaki","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R150-20250714","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.bbmt.2017.08.005","article-title":"Predictors for permanent discontinuation of systemic immunosuppression in severely affected chronic graft-versus-host disease patients.","volume":"23","author":"Curtis","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R151-20250714","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3324\/haematol.2021.279814","article-title":"Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease.","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"key":"R152-20250714","doi-asserted-by":"crossref","first-page":"578314","DOI":"10.3389\/fimmu.2020.578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: current status and future directions.","volume":"11","author":"Saidu","year":"2020","journal-title":"Front Immunol"},{"key":"R153-20250714","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sj.bmt.1705022","article-title":"Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease.","volume":"36","author":"Giaccone","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R154-20250714","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood.2021014448","article-title":"Three US Food and Drug Administration-approved therapies for chronic GVHD.","volume":"139","author":"Zeiser","year":"2022","journal-title":"Blood"},{"key":"R155-20250714","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease.","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"key":"R156-20250714","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"R157-20250714","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study.","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R158-20250714","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"R159-20250714","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease.","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"R160-20250714","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2352-3026(24)00174-1","article-title":"Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.","volume":"11","author":"Locatelli","year":"2024","journal-title":"Lancet Haematol"},{"key":"R161-20250714","doi-asserted-by":"crossref","first-page":"H235","DOI":"10.1152\/ajpheart.00014.2022","article-title":"Belumosudil, ROCK2-specific inhibitor, alleviates cardiac fibrosis by inhibiting cardiac fibroblasts activation.","volume":"323","author":"Liu","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R162-20250714","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"R163-20250714","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study.","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"key":"R164-20250714","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jtct.2021.05.004","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2020 Treatment of Chronic GVHD Report.","volume":"27","author":"DeFilipp","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R165-20250714","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41409-023-02128-8","article-title":"A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.","volume":"59","author":"Hollaender","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R166-20250714","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"R167-20250714","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbmt.2019.11.020","article-title":"Reliability and validity of the modified 7-day lee chronic graft-versus-host disease symptom scale.","volume":"26","author":"Teh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R168-20250714","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease.","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"key":"R169-20250714","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"key":"R170-20250714","article-title":"A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease. (ROCKnrol-1)."},{"key":"R171-20250714","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study.","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R172-20250714","article-title":"Front line ibrutinib without corticosteroids for newly diagnosed chronic graft-versus-host disease."},{"key":"R173-20250714","article-title":"Belumosudil for the pre-emptive treatment of patients with chronic graft versus host disease."},{"key":"R174-20250714","article-title":"BElumosudil for Bronchiolitis Obliterans Prevention\/therapy (BEBOP)."},{"key":"R175-20250714","article-title":"Ruxolitinib for early lung dysfunction after hematopoietic stem cell transplant."},{"key":"R176-20250714","article-title":"Ruxolitinib for bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT)."},{"key":"R177-20250714","article-title":"Alvelestat (MPH966), an oral neutrophil elastase inhibitor, in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation."},{"issue":"Supp 1","key":"R178-20250714","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2022-156340","article-title":"Ruxolitinib for treatment of steroid refractory sclerotic chronic graft-versus-host disease (cGVHD): results of a multicenter phase II trial.","volume":"140","author":"Bhatt","year":"2022","journal-title":"Blood"},{"key":"R179-20250714","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1200\/JCO.24.00205","article-title":"A multicenter phase II trial of ruxolitinib for treatment of corticosteroid refractory sclerotic chronic graft-versus-host disease.","volume":"42","author":"Bhatt","year":"2024","journal-title":"J Clin Oncol"},{"key":"R180-20250714","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/j.jtct.2023.12.381","article-title":"Phase 1 trial investigating the safety and tolerability of leflunomide in patients with steroid-dependent chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplant (alloHCT).","volume":"30","author":"Amandeep Salhotra","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T19:01:00Z","timestamp":1752519660000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005298","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}